ReviewAdvances in cancer research2017
Applying a Conceptual Framework to Maximize the Participation of Diverse Populations in Cancer Clinical Trials.
Review in Advances in cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Engendering trustworthiness in the community: Strategies for researchers.Journal of Alzheimer's disease : JAD · 2026Article
- Community perspectives on the return of research results and ownership of data and specimens for brain tumor genomic research.SSM. Qualitative research in health · 2026Article
- A systems framework for improving clinical trial recruitment: A literature-informed approach.Journal of clinical and translational science · 2026Article
- Community leaders' perceptions of pain and research engagement: Implications for participant diversity and inclusion in pain clinical trials.The journal of pain · 2025Article
- Community engagement in the context of cancer: scoping review of definitions and measures to inform program-level analysis.Cancer causes & control : CCC · 2025Article
- AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis.Discover oncology · 2025Article
- The relationship between trust in federal oversight of vaccine safety and willingness to participate in COVID-19 clinical trials: a repeated measures study of Philadelphia residents (September 2021 - March 2023).BMC public health · 2024Article
- Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-Assessment.JCO oncology practice · 2023Article
- Physician Perspectives on Reducing Curative Cancer Treatment Intensity for Populations Underrepresented in Clinical Trials.The oncologist · 2022Article
- Reimagining diversity in multiple myeloma clinical trials.Hematological oncology · 2022Article
- Disparities in awareness of and willingness to participate in cancer clinical trials between African American and White cancer survivors.BMC cancer · 2022Article
- A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act.Neuro-oncology · 2022Article
- Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response.British journal of clinical pharmacology · 2022Review
- Cancer Epidemiology in Hispanic Populations: What Have We Learned and Where Do We Need to Make Progress?Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Review
- Equitable Representation of Latinos in Clinical Research Is Needed to Achieve Health Equity in Cancer Care.JCO oncology practice · 2022Article
- Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.AIDS research and human retroviruses · 2022Article
- Accrual and retention of diverse patients in psychosocial cancer clinical trials.Journal of clinical and translational science · 2022Article
- Community health worker insights on promoting research engagement with diverse populations.Frontiers in public health · 2022Article
- Promoting inclusion in clinical trials-a rapid review of the literature and recommendations for action.Trials · 2021Review
- Community and Research Perspectives on Cancer Disparities in Wisconsin.Preventing chronic disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The underrepresentation of ethnically diverse populations in cancer clinical trials results in the inequitable distribution of the risks and benefits of this research. Using a case study approach, we apply a conceptual framework of factors associated with the participation of diverse population groups in cancer clinical trials developed by Dr. Jean Ford and colleagues to increase understanding of the specific strategies, and barriers and promoters addressed by these strategies, that resulted in marked success in accrual of racially and ethnically diverse populations in cancer clinical research. Results indicate that the studies presented were able to successfully engage minority participants due to the creation and implementation of multilevel, multifaceted strategies that included: culturally and linguistically appropriate outreach, education, and research studies that were accessible in local communities; infrastructure to support engagement of key stakeholders, clinicians, and organizations serving minority communities; testimonials by ethnically diverse cancer survivors; availability of medical interpretation services; and providing infrastructure that facilitated the engagement in clinical research of clinicians who care for minority patient populations. These strategic efforts were effective in addressing limited awareness of trials, lack of opportunities to participate, and acceptance of engagement in cancer clinical trials. Careful attention to the context and population characteristics in which cancer clinical trials are conducted will be necessary to address disparities in research participation and cancer outcomes. These studies illustrate that progress on minority accrual into clinical research requires intentional efforts to overcome barriers at all three stages of the accrual process: awareness, opportunity, and acceptance of participation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.